Rigel Pharmaceuticals (RIGL) Change in Intangibles (2023 - 2024)
Rigel Pharmaceuticals' quarterly Change in Intangibles came in at $222000.0 in Q2 2024, up 60.87% quarter-over-quarter from $138000.0 in Q1 2024.
Rigel Pharmaceuticals has reported Change in Intangibles for 2 years, with the latest figure at $222000.0 in Q2 2024.
- For the quarter ending Q2 2024, Change in Intangibles changed N/A year-over-year to $222000.0; the trailing twelve-month figure through Dec 2024 stood at $360000.0 (down 97.6% YoY), and the FY2024 full-year result was $360000.0, down 97.6% from the prior year.
- Change in Intangibles for Q2 2024 stood at $222000.0, up from $138000.0 in the prior quarter.
- The five-year high for Change in Intangibles was $15.0 million in Q1 2023, with the low at $138000.0 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 68,980.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 222,000.00 |
| Jun 30, 2024 | 222,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Mar 31, 2023 | 15.00 Mn |
| Mar 31, 2023 | 15.00 Mn |